Interleukin-6 and diabetes: The good, the bad, or the indifferent?

Diabetes

Volumn 54, Issue SUPPL. 2, 2005, Pages

  Kristiansen, Ole P ^a,b   Mandrup Poulsen, Thomas ^a,c  

^a STENO DIABETES CENTER   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ADIPOCYTE; APOPTOSIS; BRAIN FUNCTION; CELL DESTRUCTION; DIABETOGENESIS; DISEASE COURSE; ENERGY EXPENDITURE; GENE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; LIVER CELL; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROSECRETORY CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PANCREATITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

APOPTOSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; INTERLEUKIN-6; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION;

EID: 33644755633     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.54.suppl_2.S114     Document Type: Review

References (75)

1. Nerup J, Platz P, Andersen OO, Christy M, Lyngsoe J, Poulsen JE, Ryder LP, Nielsen LS, Thomsen M, Svejgaard A: HL-A antigens and diabetes mellitus. Lancet 2:864-866, 1974
2. Kolb H, Mandrup-Poulsen T: An immune origin of type 2 diabetes. Diabetologia 48:1038-1050, 2005
3. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813-823, 2004
4. Eizirik DL, Mandrup-Poulsen T: A choice of death: the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115-2133, 2001
5. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221-229, 2001
6. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
7. Kamimura D, Ishihara K, Hirano T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1-38, 2003
8. Kristiansen OP, Nolsøe RL, Larsen L, Gjesing AMP, Johannesen J, Larsen ZM, Lykkesfeldt AE, Karlsen AE, Pociot F, Mandrup-Poulsen T, DIEGG, DSGD: Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early onset type 1 diabetes in females. Hum Mol Genet 12:1101-1110, 2003
9. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138-18144, 2000
10. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998
11. Wang H, Zhang Z, Chu W, Cooper JJ, Elbein SC: Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J Clin Endocrinol Metab 90:1123-1129, 2005
12. Hamid YH, Urhammer SA, Jensen DP, Glumer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O: Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 53:3342-3345, 2004
13. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM: The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15:43-58, 2001
14. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC: Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300:2101-2104, 2003
15. Jahromi MM, Millward BA, Demaine AG: A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. J Interferon Cytokine Res 20:885-888, 2000
16. Eerligh P, Koeleman BPC, Dudbridge F, Bruining GJ, Roep BO, Giphart MJ: Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immun 5:36-40, 2004
17. Gillespie KM, Nolsøe RL, Betin VM, Kristiansen OP, Bingley P, Mandrup-Poulsen T, Gale EAM: Is puberty an accelerator of type 1 diabetes in interleukin 6 -174CC females. Diabetes 54:1245-1248, 2005
18. Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F: Relation of the 174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 88:1125-1128, 2001
19. Illig T, Bongardt F, Schopfer A, Muller-Scholze S, Rathmann W, Koenig W, Thorand B, Vollmert C, Holle R, Kolb H, Herder C: Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J Clin Endocrinol Metab 89:5053-5058, 2004
20. Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, Tornvall P: Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem 50:2136-2140, 2004
21. Ray P, Ghosh SK, Zhang DH, Ray A: Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett 409:79-85, 1997
22. Vozarova B, Fernandez-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK: The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112:409-413, 2003
23. Stephens JW, Hurel SJ, Cooper JA, Acharya J, Miller GJ, Humphries SE: A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. Mol Genet Metab 82:180-186, 2004
24. Hamid YH, Rose CS, Urhammer SA, Glumer C, Nolsøe RL, Kristiansen OP, Mandrup-Poulsen T, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O: Variations of the interleukin-6 promoter associates with features of the metabolic syndrome in Caucasian Danes. Diabetologia 48:251-260, 2005
25. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M: Promoter polymorphisms of the TNF-α (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872-1876, 2003
26. Mohlig M, Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher E, Bergmann MM, Ristow M, Hoffmann K, Pfeiffer AF: Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab 89:1885-1890, 2004
27. Wolford JK, Colligan PB, Gruber JD, Bogardus C: Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Genet Metab 80:338-343, 2003
28. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520, 2000
29. Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M: The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52:558-561, 2003
30. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
31. Southern C, Schulster D, Green IC: Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6: an effect distinct from that of interleukin-1. Biochem J 272:243-245, 1990
32. Sandler S, Bendtzen K, Eizirik DL, Welsh M: Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 126:1288-1294, 1990
33. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K, Hellerstrom C: Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest 93:1968-1974, 1994
34. Wadt KA, Larsen CM, Andersen HU, Nielsen K, Karlsen AE, Mandrup-Poulsen T: Ciliary neurotrophic factor potentiates the β-cell inhibitory effect of IL-1 in rat pancreatic islets: association with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes 47:1602-1608, 1998
35. Rabinovitch A, Suarez-Pinzon WL: Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev Endocr Metab Disord 4:291-299, 2003
36. Akiyama T, Takasawa S, Nata K, Kobayashi S, Abe M, Shervani NJ, Ikeda T, Nakagawa K, Unno M, Matsuno S, Okamoto H: Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation. Proc Natl Acad Sci U S A 98:48-53, 2001
37. Choi SE, Choi KM, Yoon IH, Shin JY, Kim JS, Park WY, Han DJ, Kim SC, Ahn C, Kim JY, Hwang ES, Cha CY, Szot GL, Yoon KH, Park CG: IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol 13:43-53, 2004
38. Gurr W, Yavari R, Wen L, Shaw M, Mora C, Christa L, Sherwin RS: A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice. Diabetes 51:339-346, 2002
39. Anderson JT, Cornelius JG, Jarpe AJ, Winter WE, Peck AB: Insulin-dependent diabetes in the NOD mouse model. II. Beta cell destruction in autoimmune diabetes is a TH2 and not a TH1 mediated event. Autoimmunity 15:113-122, 1993
40. DiCosmo BF, Picarella D, Flavell RA: Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in non-obese diabetic mice. Int Immunol 6:1829-1837, 1994
41. Campbell IL, Hobbs MV, Dockter J, Oldstone MB, Allison J: Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am J Pathol 145:157-166, 1994
42. Brunello AG, Weissenberger J, Kappeler A, Vallan C, Peters M, Rose-John S, Weiss J: Astrocytic alterations in interleukin-6/soluble interleukin-6 receptor α double-transgenic mice. Am J Pathol 157:1485-1493, 2000
43. Pilstrom B, Bjork L, Bohme J: Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 7:806-814, 1995
44. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817, 2003
45. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700, 2004
46. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
47. Campbell IL, Cutri A, Wilson A, Harrison LC: Evidence for IL-6 production by and effects on the pancreatic beta-cell. J Immunol 143:1188-1191, 1989
48. Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA: Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182-E187, 2004
49. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75-79, 2002
50. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167-4170, 1997
51. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK: Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005-3010, 2003
52. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067, 2004
53. Carey AL, Febbraio MA: Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 47:1135-1142, 2004
54. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997
55. Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850, 1998
56. Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, Pedersen BK: Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124:495-502, 2003
57. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362-2374, 2004
58. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003
59. Stouthard JML, Oude Elferink RPJ, Sauerwein HP: Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun 220:241-245, 1996
60. Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45784, 2003
61. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M: Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311:372-379, 2003
62. Shi H, Tzameli I, Bjorbaek C, Flier JS: Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 279:34733-34740, 2004
63. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R: Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045-1050, 2003
64. Lyngso D, Simonsen L, Bulow J: Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543:379-386, 2002
65. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, Laville M, Vidal H: Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53:2232-2241, 2004
66. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E: SOCS-3 is an insulin-induced negative regulator of insulin signalling. J Biol Chem 275:15985-15991, 2000
67. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA: Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029-1037, 2004
68. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084-2089, 2002
69. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK: Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643-1648, 2004
70. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Wolsk-Petersen E, Febbraio M: The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proc Nutr Soc 63:263-267, 2004
71. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA: Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784-2789, 2003
72. Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S, Okumura T: Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27:1296-1303, 1998
73. Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399, 2002
74. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746, 2003
75. Wallenius K, Jansson JO, Wallenius V: The therapeutic potential of interleukin-6 in treating obesity. Expert Opin Biol Ther 3:1061-1070, 2003